Every breath carries information.
We turn it into action.

Starting with lung cancer, we’re building a new standard for respiratory diagnostics.

Lung cancer is the leading cause of cancer-related deaths worldwide.

Current tools are failing patients.

Coach explaining stuff to an athlete
Coach explaining stuff to an athlete
Coach explaining stuff to an athlete
0+

million people globally are diagnosed each year

0+

million people globally are diagnosed each year

0+

million people globally are diagnosed each year

0%

of eligible people are not annually screened

0%

of eligible people are not annually screened

0%

of eligible people are not annually screened

0%

percent of patients are diagnosed at Stage IV

0%

percent of patients are diagnosed at Stage IV

0%

percent of patients are diagnosed at Stage IV

0%

5-year survival rate for Stage IV patients

0%

5-year survival rate for Stage IV patients

0%

5-year survival rate for Stage IV patients

Our CEO
Our CEO
Our CEO

OUR TECHNOLOGY


Unlocking the future of non-invasive lung cancer detection.

We’re developing a breakthrough platform that captures molecular signals from the lungs, without relying on imaging or invasive procedures. Our approach is built on a proprietary sample collection and analysis process, designed to deliver high-resolution molecular data to enable earlier, more accurate detection.

Currently in development, our platform is engineered to overcome the limitations of today’s screening tools, with the goal of making powerful respiratory diagnostics accessible and scalable in routine care.

HOW IT WORKS

01

Breath Test

At a clinician’s office, a patient provides a breath sample using the Respiro collection device. The sample takes just a few minutes to collect and is designed to capture rich molecular information from the lungs.

Breath Test

At a clinician’s office, a patient provides a breath sample using the Respiro collection device. The sample takes just a few minutes to collect and is designed to capture rich molecular information from the lungs.

Sample Processed

The sample is sent to the Respiro lab for advanced molecular analysis using our proprietary process. This step enables deep profiling of lung-derived biomarkers associated with early-stage lung cancer.

Sample Processed

The sample is sent to the Respiro lab for advanced molecular analysis using our proprietary process. This step enables deep profiling of lung-derived biomarkers associated with early-stage lung cancer.

02

03

Results Provided

Respiro then sends the results to the clinician, who works with the patient to determine the next steps and make treatment decisions.

Results Provided

Respiro then sends the results to the clinician, who works with the patient to determine the next steps and make treatment decisions.

BENEFITS


Our technology provides better insights without radiation or needles.

✓ Converts breath-based insights into a scalable screening tool for earlier, more treatable lung cancer detection.

✓ Designed for use in primary care and community settings to improve access and patient uptake.

✓ Unlocks rich molecular data from the lungs that can support drug development and clinical research.

Our CEO
Our CEO

OUR FOUNDING TEAM

Our CEO

Alison Quinn

Commercial leader with extensive experience in healthcare product development, go-to-market strategy, and commercial partnerships.

Our CEO

Dr Theo Issitt

A breath analysis expert with 15+ publications in breath and cell biology and years of experience developing and testing breath collection platforms.

With support from

Support non-invasive solutions for earlier detection, diagnoses, and precision medicine.


Created by Respiro Diagnostics

Contact us at Alison@RespiroDiagnostics.com